Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

flutamide
bicalutamide
cabazitaxel
enzalutamide
abiraterone
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time 9 months at the time of study entry.

choline
bone scan
serum testosterone
prednisone
prostatectomy
  • 496 views
  • 23 Jan, 2021
  • 68 locations
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

-releasing hormone (LHRH) analogue with the use of Whole Boby (WB) DW-MRI.

prostate carcinoma
bone scan
zoledronic acid
ct scan
luteinizing hormone
  • 109 views
  • 22 Jan, 2021
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity of chemotherapy using weekly paclitaxel (arm A) versus the combination of the cdk 4/6 inhibitor palbociclib and standard endocrine treatment (arm B). After 12 weeks treatment is switched crossover. During the 24-weekly treatment period, clinical and radiological evaluations …

lymph node metastases
metastasis
tamoxifen
cyclophosphamide
  • 3 views
  • 24 Jan, 2021
  • 4 locations
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC.

  • 0 views
  • 02 Apr, 2021
  • 4 locations